ABSTRACT: Rates of relapse in BD are high with medication nonadherence identified as an important contributor to relapse. Psychopharmacology remains a key component to the treatment of BD; therefore, increased understanding of medication use and ways to promote greater adherence is essential. The aim of the study was to identify how participants with BD experience taking prescribed medication. Participants had BD I or BD II, were users of specialist mental health services, aged 18-64 years, euthymic, mildly hypomanic or depressed, and on any combination of medication. Exclusion criteria were minimal. A semistructured interview was completed exploring patients' views of BD and factors influencing adherence based on the Subjective Experience of Medication Interview. An inductive thematic analysis was used to identify themes. The study participants (n = 36) had predominantly bipolar I (78%) and were female (69%), and of New Zealand European ethnicity (67%) with 14% Maori. The mean age was 41 years (SD: 12.0). Findings from the thematic analysis generated three themes: Learning about the clinical meaning of having BD, Understanding how to use medication, and Understanding what works for me. The qualitative nature of our study limits the generalizability of our findings to a broader population of individuals with BD. The participants developed confidence in being in charge of their BD through a process of learning about BD and medication and understanding what this meant for them. The findings support greater emphasis on collaborative approaches that recognize the expertise of the individual with BD and the clinician.
INTRODUCTION
Bipolar disorder (BD) is a long-term and cyclic mood disorder that is particularly complex in its characteristics and treatment (Frank et al. 2000; Malhi et al. 2009 ). Rates of recurrence in BD are high with~50% of individuals with BD experiencing a recurrence within 2 years of achieving recovery (Perlis et al. 2006 ). An important contributor to recurrence and relapse in BD is medication nonadherence (Goodwin & Jamison 2007) . Additionally, nonadherence has been associated with a range of other poor clinical outcomes including higher rates of hospital admissions (Marken et al. 1992) , higher rates of suicide , and recurrence of acute episodes, particularly mania (Miklowitz 2008) .
BACKGROUND
Adherence refers to the extent to which the patient's behaviour matches agreed recommendations from the prescriber. Nonadherence can be in the form of reducing dosages, reducing frequency, using symptomatically rather than as a prophylactic, temporary cessation, and full cessation (Horne 2006) . The broad range of factors that impact on adherence to medication in BD are well established and extend across domains of patient-related factors, illness factors, treatment factors, and environmental factors (Busby & Sajatovic 2010; Crowe et al. 2011; Goodwin & Jamison 2007; Leclerc et al. 2013) . Patient-related factors address an individual's personal attitudes and beliefs which include beliefs about the need for treatment, beliefs about themselves and their capacity to have control over the disorder, and adjusting to having a long-term illness (Adams & Scott 2000; Clatworthy et al. 2009; Pope & Scott 2003; Scott 2002) . Illness factors relate to the severity of illness and the level of acceptance of having a long-term condition Sajatovic et al. 2008 Sajatovic et al. , 2009a . Treatment issues relate to perceived benefits of medication, doubts about the need for medication, lack of adequate information about medication, concerns with negative side effects, and future adverse effects Jonsdottir et al. 2009; Rosa et al. 2007) . Environmental factors include impact of family, extent of follow-up care, and the quality of the therapeutic relationship (Darling et al. 2008; Zeber et al. 2008) .
Management of BD is challenging given the complicated and variable nature of the disorder (Malhi et al. 2009 ). Psychopharmacology continues to be key component to its management (Malhi et al. 2015) ; therefore, increased understanding of medication use and ways to promote greater adherence is essential. Medication taking is clearly a complex behaviour with multiple influences (Brown & Bussell 2011; Leclerc et al. 2013; Van Camp et al. 2016) . Previous studies on medication adherence identifying determinants of adherence have predominantly used quantitative measures to explore particular variables hypothesized to impact on adherence. This study takes a different position and explores medication use from the individual's perspective in the context their personal and unique experiences of having BD. The intention is to provide greater understanding of the factors influencing individuals' decisions regarding medication use.
METHOD Aim
To identify how participants with BD experience taking prescribed medication.
Sample
Participants with BD I and BDII (DSM-IV) were recruited from specialist mental health services across urban and rural settings and self-referral. The participants were current or previous users of specialist community mental health services. Participants for this qualitative study were drawn from a larger quantitative study on medication adherence (yet to be completed) undertaken in New Zealand. Inclusion criteria for the study included: (a) age 18-64 years and (b) able and willing to sign informed consent for the research protocol. At the time of signing informed consent, participants needed to be euthymic, mildly hypomanic or depressed, and on any combination of medication. Exclusion criteria included: (a) schizophrenia and (b) severe alcohol or drug dependence.
Thirty-six participants took part in this qualitative study consisting of the first 19 participants who entered the larger quantitative study with purposeful sampling of a further 17 participants to ensure ethnic and mental health service status representations. Following written informed consent, patients were allocated a research ID number. A baseline assessment was completed by a research nurse consisting of the Structured Clinical Interview for the DSM-IV-Patient version 2.0 (SCID I/P version 2.0) (First et al. 1996) which was used to confirm DSM-IV BD diagnosis. Ethical approval was provided by the Upper South B Regional Ethics Committee (URB/10/11/044).
Data collection
A qualitative semistructured interview was completed with participants addressing self-management, attribution of illness, health service experiences, and medication adherence. The medication adherence aspect used the medication questions in the Subjective Experience of Medication Interview (Jenkins et al. 2005) as the basis of the interview to provide a structure for participants to describe their medication use. 
Thematic analysis
The process of thematic analysis used has been described by Crowe et al. (2015) . It involves the researchers becoming closely familiar with the data by reading and rereading the interview transcripts. This enabled the generation of initial codes which were clustered into related ideas (categories). The categories were then pulled together to generate themes. Once each theme is clearly defined and described, it needs to be illustrated with reference to the transcripts. The final phase can be described as the process of synthesis. This was an inductive process in that the meanings associated with medication adherence were identified across the transcripts as opposed to a deductive approach which would have involved presenting the participants' responses to the interview questions. The inductive approach tells the participant's story rather than their responses to the researcher's questions.
RESULTS

Demographic
The study participants (n = 36) predominantly had bipolar I (78%) and were female (69%). Sixty-seven per cent were of New Zealand European ethnicity and 14% Maori. The mean age was 41 years (SD: 12.0). Fourteen percent of the participants were currently involved in mental health services, 38% discharged within the last month, and 28% having had past service use. The mean age at onset of BD was 21.5 (SD: 10.9) years with a mean length of illness of 19.6 (SD: 11.8) years. All participants were not in episode at baseline apart from one individual with mild hypomania. Three themes which reflected the participants' experiences of taking medication for BD were generated by the process of thematic analysis. These themes were as follows: Learning about the clinical meaning of having BD; Understanding how to use medication; and Understanding what works for me.
Learning about the clinical meaning of having bipolar disorder
This theme describes the participants' needs for a theoretical understanding of the role of medication and BD. It involved being given information about both the disorder and the prescribed medication. Participants described a need to know what having the diagnosis meant for them. This participant was shocked by the diagnosis and had little understanding of either BD or the role of medication.
I had never heard of any kind of condition like this before, I never knew that you could take a pill that would change the way that you would feel, it was really confusing for me, I just did not get it at all . . . I didn't know what lithium was, I didn't know what Prozac was, I was really green, I was really na€ ıve.
The long-term need for medication was difficult for many participants to comprehend. It often took subsequent episodes of illness before they realized that it was an episodic and ongoing disorder rather than a one-off episode.
[BD] really didn't kick in until I had the babies . . . it didn't really start until I was in my 30's so it was after the babies. I was medicated for eight months after [first baby] and six months after [second baby]. I thought I am fine now because I didn't click that this was an ongoing thing and so then I had another episode when [first baby] went to school . . . so that's when I realised that I might have to stay on medication longer.
The way in which this participant described being 'medicated' suggested that she was a passive participant in the process which was reflected in a number of participants' descriptions of the early phases of treatment. Understanding the 'prophylactic' action of medications was difficult for some participants as they thought that the use of medication was limited to when they were unwell.
I always thought that once I get off the medication I would be fine, I used to have that mentality that I only needed [medication] when I was unwell so when I don't need it I will be well.
After developing an understanding of BD as a disorder requiring ongoing medication use, many were surprised that despite what they had been told, medication had a limited role in the management of the disorder.
I think during that two year period I didn't quite understand that medication only plays a certain about, a certain role the rest is kinda [sic] getting your head around things, understanding the illness and your lifestyle. I was waiting to be cured and that didn't happen of course.
This theme captured how participants engaged first with the clinician's understanding of BD and the role of medication. It describes that how they engaged with this understanding of BD as a biological process as a way of ascribing meaning to their experiences. The emphasis in this theme was about having to come to terms with what they had been told by clinicians about the diagnosis and need for medication.
Understanding how to use medication
This theme describes the way in participants moved from an initial passive acceptance of medication to understanding what the diagnosis meant in the context of their own experiences. It was moving from knowing about BD and medication generally to understanding what this meant for them in the unique context of their lives. This involved participants, in consultation with clinicians, identifying the right medication and the right dose.
The first step in this process involved accepting the need for medication.
I spent a long time being very anti-meds so when I finally accepted it was more like I was begging them to give me something to make it stop. And so they did and it broke that really deep depression and that's what I wanted it to do. So it has kind of given me chance to find normal.
This participant described a very unpleasant process of attempting to find a medication and dosage that worked for her. She described working together with the clinician in a process of trial and error experimentation.
That 2½ year journey that I went through is what I refer to as going to hell and back because that was the trialling of medication. I hated it because we went to first to Fluoxetine, we went to Lithium; we trialled a whole combination of cocktails and nothing seemed to fit or I wasn't seeing the benefit and then we would have to wait for a therapeutic level to be reached.
The trial and error approach was described by most participants as the process by which clinicians had selected their medication regime.
Over the past six months we've been working to come down on the dose of medication. The idea of being to get to half the dose of my Venlafaxine and a third of a dose of my Quetiapine. But we've had to stop a half of both them, only in the last week. We think probably had our first wee blip, um, and had to go up and I think that's the end of, what we found at the moment, the level of medication that I require.
When participants experienced the desired effects from medication, this reinforced the need to continue taking it.
I'm improving. Ever since I've been on Lithium, my life has been so much better . . . it makes me feel normal again . . . I just want to keep that going, I'm not going to stop taking it.
When medication enabled the participants to feel 'normal', they were more likely to be adherent. However, many were tempted to stop taking their medications when they felt 'normal'. The experience of a relapse prompted some to reconsider this approach.
Because I have been off them and when I was off them I was very unwell so I know that I need them.
This understanding of the effects of different medications on them as individuals rather than the generic description of how they work provided the impetus to remain on the medications that were working for them.
They stabilise me, stabilise the fluctuation of lows and highs and make me more functioning and be able to interact in relationships . . . I don't think there is a cure, you know I don't think there is a cure at all but that's all you can do is be more functioning.
While some medications had benefits, they also had side effects. Participants described the lifestyle impact of the side effects of some medications.
I don't like the idea of it making me heavier. . . I don't know whether that is because it slows your metabolism or whether it makes you eat more . . . It's a bit annoying if you are taking something that is working against that. Some expressed concerns about the possible longterm side effects of taking some of the medications.
The other concern I do have is the long-term effects I mean sometimes you can be taking something for a longtime and all of a sudden they discover oh they have found that taking this medication results in such and such.
The development of an understanding of how to use medication needed to occur in the context of their lifestyle, and they described strategies for integrating their use into this.
I can't take my medication after 8.30 otherwise I have a stupefied feeling the next day umm which limits me from going to the movies at 8.30 or going out for dinner or like people might get home at 10.30 if they are going out for a meal I can't . . . It would always have to be on a Friday or Saturday so I could sleep the next day or sleep in the next day so everything has to be measured and everything has to be I mean everything involves thought, I just can't throw caution to the wind While some participants described the positive effects of medication use, those that experienced side effects or disruptions to lifestyle were often less positive about their continued use. This theme described how participants moved from being told generic information about the medication to understanding what this meant in the context of their manifestation of BD and their lifestyle. This theme also revealed that participants responded to a collaborative approach. They described this phase of the process of taking medication in terms of 'we', and it was a less passive phase in understanding what it meant for them.
Understanding what works for me
This theme describes how participants 'took charge' in making decisions about their use of medication. The participants' actions reflected the process of weighing up the risks and benefits of the medication as prescribed, making choices in the way they used medication in a way that fitted with their lifestyle. The theme also encompassed other choices they made to manage their illness beyond using medication.
Participants described ongoing adherence as an active process for which they took responsibility.
This time see I tried to go off it in January which was just before the children went to school. The night before they went to school I didn't sleep and that was really weird . . . sometimes it just takes something little so I thought right there is no rush [to stop] Making decisions about adhering to their medication involved weighing up the pros and cons.
The main thing was, um, it's just a bit personal but just the libido and stuff . . . it makes it hard because I don't have the full reward [from sex] like I would without medication . . .and I think 'oh shit, maybe I do need it [medication]'. Partial adherence was also described by some participants where they made decisions about increasing or decreasing their doses when experiencing an increase in symptoms.
I've actually been naughty at times when I've self-medicated with my meds if I hit a low patch. Like I think it was only about 3 weeks ago that I, I just couldn't motivate myself do anything. It was horrible. I felt so blah, I
was tearful all the time and I felt sorry for my baby cause I didn't even want to get up in the morning . . . and so for about 3 days I doubled my medication and then I went back down again and I was fine.
Some participants reflected a requirement to develop confidence in understanding their own needs.
I haven't reached that desired confidence to not be without them just yet because I am still learning a lot about them . . . I haven't got that ability to be strong to cope without them. Not yet.
Taking control for most participants meant not only taking control of their medication but also realizing that medication was only a partial answer to managing their BD. It also involved knowing their own triggers and early warning signs and having strategies to manage these.
Obviously medication is playing a big part up to this point in terms of getting me to a point where I am stable enough to be able [to manage myself]. It's just being aware of the times and aware of your triggers and monitoring it.
Staying well was the focus of all the participants' descriptions of their relationship with medication use.
The question is I need to stay well, how do you do that? Take the medication ok. What are your triggers? How do you know you are becoming unwell? Loss of sleep, racy thoughts. You know I know myself well enough to know when things are starting to go down for me so the key for me in all this is wellness.
The theme Understanding what works for me captured how participants described an active role in medication decision-making. The participants moved through a process that involved learning about BD and medication from the clinician's perspective, to working with the clinician to understand what BD and medication meant for them in their lives, to a point where they felt more in control by understanding what was happening and having some strategies to manage this.
DISCUSSION
The findings from this qualitative study describe the process participants went through which informed their decisions about their use of medication for BD. There was a shift from passive learning to a more active process of understanding what having BD meant and the role of medication in the context of their lives which lead to increased confidence in being in charge of their BD. The participants were actively engaging in a process that occurred over time where they could make sense of their experiences to inform their choices, integrate these into their lifestyle, and identify 'what works for me'. The participants in this study did not lack insight into their disorder, a presumption often made about adherence (El-Mallakh 2007; Yen et al. 2005) , but were using their own knowledge and experience to inform their decisions about medication use.
There have been few qualitative studies that have explored medication use from the individual's subjective experiences. Clatworthy et al. (2007) undertook a small qualitative study of 13 participants using a semistructured interview and coded their findings in relation to predetermined criteria based on illness representations (identify, timeline, cause, consequences, and control/cure) and the Necessity-Concerns Framework (perceptions of treatment and concerns of adverse effects). Similar to our study, Sajatovic et al. (2009b) used the medication questions from the Subjective Experience of Medication Interview to structure their semistructured interview. However, in contrast to us, they used a deductive content analysis approach specifically based on the three questions. Our study used an inductive approach which tells the participant's story rather than their responses to the researcher's questions. This is the first study that we are aware of that has used such an approach to understand medication use in BD.
Understanding the perspectives that people with BD have of their medication is very important for mental health nurses to be able to establish effective therapeutic relationships. Participants described a process of moving from a fairly passive role of accepting whatever was told to them about the need for medication to a position where they were actively engaged in making their own choices about when and how to use medication. This provides an important context for how nurses engage with people with BD at different stages of the person's journey. Nurses need to identify where people with BD are in relation to passive acceptance or active involvement in medication decision-making in order to work with them in relation to medication adherence.
The experiences of medication adherence described by the participants in our study reflected factors previously identified in relation to concerns about side effects and future adverse effects Jonsdottir et al. 2009 ), lack of adequate information , varied beliefs about the need for treatment (Adams & Scott 2000; Sajatovic et al. 2009b) , and adjusting to having a long-term condition (Pope & Scott 2003) . Their descriptions illustrated that adherence to medication evolved from a process of making sense of their medication-taking experiences, weighing up the positives and negatives, and making an active decision regarding their use of medication.
The dominant approach to medication adherence is psychoeducation which focuses on changing behaviours and attitudes through increasing the individual's awareness and understanding of BD including the importance of adherence to treatment (Stafford & Colom 2013) . While there is evidence to support psychoeducation as an effective approach in improving medication adherence (Berk et al. 2010; MacDonald et al. 2016) , the evidence for sustained improvement is weak (Bond & Anderson 2015) . Additionally, there are significant dropout rates reported in psychoeducation programmes (Leclerc et al. 2013) , suggesting a mismatch between the approach and the needs of those attending. This may relate to an overemphasis on the medical model which is illness-focused and fails to account for individual issues and needs and situates the patient as a passive recipient (Wilson et al. 2017) . These approaches can underestimate the capacity for the individual to explore and make sense of their experiences such as ambivalence and contradictions that have been identified as part of the experience of BD (Inder et al. 2008) . It has also been recommended that interventions using a psychoeducation focus need to more fully incorporate the knowledge and beliefs that individuals hold (MacDonald et al. 2016) and findings from our current study would endorse this.
Our findings that medication use is an active process align with Deegan and Drake (2006) who describe taking medication as 'a dynamic journey, not a static event ' (p. 1636) . They propose that decision-making requires a collaborative approach that recognizes the expertise of both parties and suggest a model of shared decision-making which brings together empirical evidence with the unique issues, values, and contexts of the individual. The empirical evidence needs to accurately portray the relative importance of medication in achieving clinical recovery in the context of its efficacy in reducing symptoms and relapses. Historically, BD was seen as a genetically based biological condition. This has largely dictated a view in which medication was seen not just as the primary therapy but the only therapy (Scott 2006) . There has been considerable support for a greater collaborative approach between individuals with BD and their treating clinicians as a key component to successful management of this disorder (Berk et al. 2010; Crowe et al. 2011) . In our study, participants used the term 'we' when they were referring to more collaborative approaches. However, a collaborative approach extends beyond this and allows for the individuals with BD to be active partners in decision-making rather than positioning them as passive recipients of medical orders (Crowe et al. 2012) . It allows individuals to have their lived experience recognized by being active in determining targets of therapy, providing their perspective in treatment, making choices about what they think may be effective, and being entitled to follow their treatment choice even it differs with the clinician (Murray et al. 2011) . Notably, support for a collaborative approach has been reflected in clinical guidelines such as The Royal Australian and New Zealand College for Psychiatrists clinical practice guidelines for mood disorders (Malhi et al. 2015) which state 'a critical treatment context in the treatment of mood disorders is the person with the disorder. A key clinical challenge is to optimally integrate the clinician's "technical" expertise with the patient's "lived experience" expertise of the disorder' (p. 1103).
Living well with BD extends beyond clinical recovery, where there is a reduction of symptoms and relapses, to entail functional recovery and personal recovery. Functional recovery constitutes improved emotional regulation, circadian rhythmicity, improved self-esteem, and improved social and occupational relations (Samalin et al. 2014) , and personal recovery reflects an individual's psychological adaptation to the disorder (Tse et al. 2014) . A recovery framework emphasizes the importance of individuals taking responsibility for their wellness and recognizes individuals can live fulfilling lives despite experiencing symptoms (Todd et al. 2012) .
Addressing medication adherence within a recovery framework allows individuals with BD to find meaning from their experiences in the context of sound knowledge of the illness and treatments, having some control over life through choice, the ability to take personal responsibility through engaging in self-management, and involvement in decision-making in all aspects of care including goal setting and strategies for medication use.
The qualitative nature of our study limits the generalizability of our findings to a broader population of individuals with BD. In addition, the sample was predominantly female and had BDI and therefore may not reflect the experiences of males with BD or those with BDII or BD not otherwise specified. Our sample did include a proportion of individuals with BD of Maori ethnicity, although we did not identify any strong differences in experiences of medication.
CONCLUSION
Findings from this study suggest that for individuals with BD, decisions about medication use occur in a broader context of making sense of their experiences and developing greater confidence in being in charge of their BD. Enhancing medication adherence may be facilitated by a greater emphasis on collaborative approaches that recognize the expertise of both the individual with BD and the clinicians. This is particularly relevant to the role of mental health nurses. It is also important adherence is viewed within a broader context of a recovery framework rather than from a more narrow medical discourse.
RELEVANCE TO CLINICAL PRACTICE
Increasing understanding of medication use and ways to promote greater adherence is important in reducing relapses in BD. Mental health nurses have a key role in promoting medication adherence; therefore, it is important they have an understanding of how people with BD use prescribed medication. Individuals with BD need to be supported to make sense of their experiences of their illness, the role of medication, and other factors that influence their illness. Mental health nurses are in a position to promote collaborative approaches that recognize the expertise of both the individual with BD and the clinician.
